FINWIRES · TerminalLIVE
FINWIRES

Changchun High-Tech Industry Subsidiary Gets China Clinical Trial Nod for Growth Hormone Drug

-- China's drug regulator approved Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Jinsai Pharmaceutical's clinical trial for its GS3-007a dry suspension, according to a Friday filing with the Shenzhen bourse.

The drug promotes growth hormone secretion, helping treat idiopathic short stature, the filing said.

Related Articles